Despair, pain, and loss were rampant during the 1980s and early 1990s, at the beginning of South Africa’s HIV epidemic. Witnessing this helped catalyse me to undertake one of the earliest population-based studies that looked closely at this emerging health issue in South Africa. Meanwhile, cases continued to surge in South Africa at an alarming rate, doubling annually in the general population. CAPRISA’s research on PrEP was recently recognised by the VinFuture Prize as a lifesaving innovation from the global South. Today, Tenofovir is taken daily as a pill for HIV prevention, a solution also known as pre-exposure prophylaxis (PrEP).

Source: The Guardian July 25, 2022 04:51 UTC